Daniel J Drucker
Overview
Explore the profile of Daniel J Drucker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
285
Citations
22925
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Muller T, Adriaenssens A, Ahren B, Bluher M, Birkenfeld A, Birkenfeld A, et al.
Mol Metab
. 2025 Mar;
95:102118.
PMID: 40024571
Background: Glucose-dependent insulinotropic polypeptide (GIP) was the first incretin identified and plays an essential role in the maintenance of glucose tolerance in healthy humans. Until recently GIP had not been...
2.
Hammoud R, Kaur K, Koehler J, Baggio L, Wong C, Advani K, et al.
JCI Insight
. 2024 Dec;
10(3).
PMID: 39723966
Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) are gut-derived peptide hormones that potentiate glucose-dependent insulin secretion. The clinical development of GIP receptor-GLP-1 receptor (GIPR-GLP-1R) multiagonists exemplified by tirzepatide...
3.
Xu Y, Michalowski C, Koehler J, Darwish T, Guccio N, Alcaino C, et al.
Sci Adv
. 2024 Dec;
10(50):eadq9909.
PMID: 39671480
Modulating the endogenous stores of gastrointestinal hormones is considered a promising strategy to mimic gut endocrine function, improving metabolic dysfunction. Here, we exploit mouse and human knock-in and knockout intestinal...
4.
Wean J, Kowalsky A, Laker R, Will S, Drucker D, Rhodes C, et al.
Mol Metab
. 2024 Nov;
95:102074.
PMID: 39612941
Objectives: Dual incretin agonists are among the most effective pharmaceutical treatments for obesity and type 2 diabetes to date. Such therapeutics can target two receptors, such as the glucagon-like peptide-1...
5.
Roell W, Coskun T, Kim T, OFarrell L, Martin J, Nason S, et al.
Mol Metab
. 2024 Nov;
91():102073.
PMID: 39603505
Objective: Glucagon is a crucial regulator of glucose and lipid metabolism as well as whole-body energy balance. Thus, modulation of glucagon receptor (GCGR) activity in the context of single-molecule multi-receptor...
6.
7.
Toki S, Abney M, Zhang J, Rusznak M, Warren C, Newcomb D, et al.
Allergy
. 2024 Nov;
79(12):3373-3384.
PMID: 39559998
Background: Anti-inflammatory effects of incretin signaling through the glucagon-like peptide-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR) in mice have been reported. Therefore, we hypothesized that signaling through...
8.
Ray P, Moggridge J, Weisman A, Tadrous M, Drucker D, Perkins B, et al.
Can J Diabetes
. 2024 Nov;
PMID: 39486576
Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are effective medications for type 2 diabetes mellitus (T2DM) and obesity, yet their uptake among patients most likely to benefit has been slow. Methods:...
9.
Liao C, Ji M, Wang Z, Drucker D, Liang H, Locksley R
bioRxiv
. 2024 Oct;
PMID: 39463951
One-sentence Summary: Intestinal telocyte TSLP relays signals from enteroendocrine cells to ILC2s to amplify the tuft cell circuit in response to feeding.
10.